Los Angeles Capital Management LLC Has $1.17 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Los Angeles Capital Management LLC reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYSFree Report) by 36.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,123 shares of the company’s stock after selling 5,839 shares during the period. Los Angeles Capital Management LLC’s holdings in Krystal Biotech were worth $1,174,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in KRYS. State Street Corp raised its position in Krystal Biotech by 52.3% during the first quarter. State Street Corp now owns 1,068,656 shares of the company’s stock valued at $71,108,000 after purchasing an additional 366,855 shares in the last quarter. Jennison Associates LLC raised its position in Krystal Biotech by 485.0% during the third quarter. Jennison Associates LLC now owns 340,849 shares of the company’s stock valued at $39,538,000 after purchasing an additional 282,583 shares in the last quarter. Driehaus Capital Management LLC raised its position in Krystal Biotech by 268.2% during the second quarter. Driehaus Capital Management LLC now owns 198,593 shares of the company’s stock valued at $23,315,000 after purchasing an additional 144,661 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Krystal Biotech by 74.2% during the first quarter. Dimensional Fund Advisors LP now owns 262,463 shares of the company’s stock valued at $17,465,000 after purchasing an additional 111,822 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its position in Krystal Biotech by 185.0% during the second quarter. Nuveen Asset Management LLC now owns 150,839 shares of the company’s stock valued at $17,708,000 after purchasing an additional 97,908 shares in the last quarter. 82.30% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $111.25 on Thursday. Krystal Biotech, Inc. has a twelve month low of $70.51 and a twelve month high of $133.60. The company’s fifty day moving average is $117.38 and its 200 day moving average is $117.39.

Krystal Biotech (NASDAQ:KRYSGet Free Report) last issued its quarterly earnings data on Monday, November 6th. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $3.89. The business had revenue of $8.60 million during the quarter, compared to the consensus estimate of $6.29 million. During the same period in the prior year, the firm earned ($1.17) EPS. The business’s revenue for the quarter was up 8500.0% compared to the same quarter last year. Analysts expect that Krystal Biotech, Inc. will post -3.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KRYS. The Goldman Sachs Group began coverage on shares of Krystal Biotech in a report on Monday, November 20th. They set a “buy” rating and a $160.00 price target for the company. Cantor Fitzgerald upped their price target on shares of Krystal Biotech from $160.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, December 13th. Finally, Citigroup began coverage on shares of Krystal Biotech in a report on Thursday, October 12th. They set a “buy” rating and a $160.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and a consensus price target of $148.78.

Read Our Latest Stock Report on KRYS

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 2,500 shares of the business’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total value of $325,000.00. Following the sale, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,632,280. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Krystal Biotech news, CAO Kathryn Romano sold 2,500 shares of the company’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total transaction of $325,000.00. Following the sale, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,632,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $105.67, for a total transaction of $2,641,750.00. Following the sale, the insider now directly owns 1,574,206 shares in the company, valued at approximately $166,346,348.02. The disclosure for this sale can be found here. 17.00% of the stock is currently owned by insiders.

About Krystal Biotech

(Free Report)

Krystal Biotech, Inc, a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.

Read More

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYSFree Report).

Institutional Ownership by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.